Transparency Life Sciences
New York
About Transparency Life Sciences
Transparency Life Sciences, the first all-digital clinical development services company, harnesses crowdsourcing and mobile health technology to advance biopharma drug candidates through clinical trials with unprecedented patient relevance and efficiency. The TLS model is highly scalable and is designed to increase current industry margins of a wasteful process that often collects irrelevant data. Drug companies will outsource an estimated $38B of clinical trial services to CROs by 2020, with a CAGR of 9-10%. Yet this robust growth masks significant customer dissatisfaction. Sponsors want clinical trials to be better-designed, technologically advanced, patient-centric, and significantly less expensive, yet change has been limited by an inability to see beyond the current outmoded, site-centric model. As a consequence, only select compounds are being developed in humans, leaving many potential important therapies untested in clinical trials. Rapid advances in digital technology and strong regulatory support create a historic opportunity for TLS to catalyze a fundamental transformation, significantly improving the quality of clinical trials while reducing their cost.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $5.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Feb 2018)
- Website: transparencyls.com
- Phone: (917) 355-9234
Industries & Categories
Biotechnology, Clinical Trials, Crowdsourcing, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/transparency-life-sciences-182168 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.